KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMY) Share-based Compensation (2016 - 2025)

Bristol Myers Squibb (BMY) has disclosed Share-based Compensation for 17 consecutive years, with $133.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation rose 10.83% to $133.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $553.0 million, a 9.07% increase, with the full-year FY2025 number at $553.0 million, up 9.07% from a year prior.
  • Share-based Compensation was $133.0 million for Q4 2025 at Bristol Myers Squibb, down from $139.0 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $157.0 million in Q2 2021 to a low of $107.0 million in Q1 2022.
  • A 5-year average of $130.9 million and a median of $132.5 million in 2021 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: fell 29.14% in 2022, then increased 18.1% in 2023.
  • Bristol Myers Squibb's Share-based Compensation stood at $133.0 million in 2021, then fell by 10.53% to $119.0 million in 2022, then rose by 6.72% to $127.0 million in 2023, then fell by 5.51% to $120.0 million in 2024, then rose by 10.83% to $133.0 million in 2025.
  • Per Business Quant, the three most recent readings for BMY's Share-based Compensation are $133.0 million (Q4 2025), $139.0 million (Q3 2025), and $137.0 million (Q2 2025).